Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, Naiyer A., Hellmann, Matthew D., Snyder, Alexandra, Kvistborg, Pia, Makarov, Vladimir, Havel, Jonathan J., Lee, William, Yuan, Jianda +16 more·2015·Science

DOI 10.1126/science.aaa1348

Cited by (1,051)

Items 801–900 of 1,051

Lung Cancer in the Era of Precision Medicine
Katerina A. Politi, Roy S. Herbst · 2015 · Clinical Cancer Research
The Pancreatic Cancer Microenvironment
Stephanie K. Dougan · 2017 · The Cancer Journal
Recent progress in Lynch syndrome and other familial colorectal cancer syndromes
Patrick McKay Boland, Matthew B.B. Yurgelun, Clement Richard Boland · 2018 · CA A Cancer Journal for Clinicians
Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?
Qiao, Meng, Jiang, Tao, Liu, Xinyu, Mao, Shiqi, Zhou, Fei, Li, Xuefei, Zhao, Chao, Chen, Xiaoxia, Su, Chunxia, Ren, Shengxiang et al. · 2021 · Journal of Thoracic Oncology
Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets
Benjamin Adam Weinberg, Joanne Xiu, Michael R. Lindberg, Anthony Frank Shields, Jimmy J. Hwang, Kelsey Anne Poorman, Mohamed E. Salem, Michael Jon Pishvaian, Randall F. Holcombe, John Lindsay Marshall et al. · 2019 · Journal of Gastrointestinal Oncology
Commensal bacteria stimulate antitumor responses via T cell cross-reactivity
Catherine Ami Bessell, Ariel Isser, Jonathan J. Havel, Sangyun Lee, David R. Bell, John W. Hickey, Worarat Chaisawangwong, Joan Glick Bieler, Raghvendra Mohan Srivastava, Fengshen Kuo et al. · 2020 · JCI Insight
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
Skoulidis, Ferdinandos, Araujo, Haniel A., Do, Minh Truong, Qian, Yu, Sun, Xin, Galan-Cobo, Ana, Le, John T., Montesion, Meagan, Palmer, Rachael, Jahchan, Nadine et al. · 2024 · Nature
Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis
Wouter Hendrickx, Ines Simeone, Samreen Anjum, Younes Mokrab, François Bertucci, Pascal Finetti, Giuseppe Curigliano, Barbara Seliger, Luigi Cerulo, Sara Tomei et al. · 2017 · OncoImmunology
Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma
Mohamed E. Salem, Alberto Puccini, Joanne Xiu, Derek Raghavan, Heinz‐Josef Lenz, Wolfgang Michael Korn, Anthony Frank Shields, Philip A. Philip, John Lindsay Marshall, Richard M. Goldberg · 2018 · The Oncologist
Treatment advances in small cell lung cancer (SCLC)
Saiama Naheed Waqar, Daniel Morgensztern · 2017 · Pharmacology & Therapeutics
Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors
Wenyan Zhong, Jeremy S. Myers, Fang Wang, Kai Wang, Justin Lucas, Edward C. Rosfjord, Judy Lucas, Andrea T. Hooper, Sharon Yang, Lu Lemon et al. · 2020 · BMC Genomics
The tumor microenvironment’s role in the response to immune checkpoint blockade
Konstantinos Aliazis, Anthos Christofides, Rushil Shah, Yao Yu Yeo, Sizun Jiang, Alain Charest, Vassiliki A. Boussiotis · 2025 · Nature Cancer
Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma
Kazuki Takada, Tatsuro Okamoto, Fumihiro Shoji, Mototsugu Shimokawa, Takaki Akamine, Shinkichi Takamori, Masakazu Katsura, Yuzo Suzuki, Takatoshi Fujishita, Gouji Toyokawa et al. · 2016 · Journal of Thoracic Oncology
The Role of the Core Non-Homologous End Joining Factors in Carcinogenesis and Cancer
Brock J. Sishc, Anthony J. Davis · 2017 · Cancers
Clinical and immunological effects of mRNA vaccines in malignant diseases
Annkristin Heine, Stefan Juranek, Peter Brossart · 2021 · Molecular Cancer
A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort
Nour‐Al‐Dain Marzouka, Pontus Eriksson, Carlos Rovira, Fredrik Liedberg, Gottfrid Sjödahl, Mattias Höglund · 2018 · Scientific Reports
Current issues and perspectives in PD-1 blockade cancer immunotherapy
Kenji Chamoto, Ryusuke Hatae, Tasuku Honjo · 2020 · International Journal of Clinical Oncology
Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer
Romualdo Barroso‐Sousa, Tanya Elizabeth Keenan, Sònia Pernas, Pedro Exman, Esha Jain, Ana Christina Garrido-Castro, Melissa E. Hughes, Brittany Bychkovsky, Renato Umeton, Janet L. Files et al. · 2020 · Clinical Cancer Research
Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild-type advanced non-small cell lung cancer
Xiaoxiao Peng, Ruoying Yu, Xue Wu, Shuyu Wu, Can Pi, Zhihong Chen, Xu‐Chao Zhang, Cun-Yi Gao, Yang Washington Shao, Li Liu et al. · 2020 · Journal for ImmunoTherapy of Cancer
Glutaminase inhibition impairs CD8 T cell activation in STK11-/Lkb1-deficient lung cancer
Sarah A. Best, Patrick M. Gubser, Shalini Sethumadhavan, Ariena J. Kersbergen, Yashira L. Negrón Abril, Joshua E. Goldford, Katherine Sellers, Waruni Abeysekera, Alexandra L. Garnham, Jackson A. McDonald et al. · 2022 · Cell Metabolism
Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)
Zhijie Wang, Lin Wu, Baolan Li, Ying Cheng, Xiaoling Li, Xicheng Wang, Liang Han, Xiaohong Wu, Yun Fan, Yan Yu et al. · 2022 · Journal of Clinical Oncology
The function and dysfunction of memory CD 8+ T cells in tumor immunity
James L. Reading, Felipe Gálvez‐Cancino, Charles Swanton, Álvaro Lladser, Karl S. Peggs, Sergio A. Quezada · 2018 · Immunological Reviews
Melanoma: What do all the mutations mean?
Elizabeth J. Davis, Douglas Buckner Johnson, Jeffrey Alan Sosman, Sunandana Chandra · 2018 · Cancer
Landscape of Immune Microenvironment Under Immune Cell Infiltration Pattern in Breast Cancer
Qianhui Xu, Shaohuai Chen, Yuanbo Hu, Wen Huang · 2021 · Frontiers in Immunology
Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma
Panda, Anshuman, de Cubas, Aguirre A., Stein, Mark, Riedlinger, Gregory, Kra, Joshua, Mayer, Tina, Smith, Christof C., Vincent, Benjamin G., Serody, Jonathan S., Beckermann, Kathryn E. et al. · 2018 · JCI Insight
Clinicopathologic Features of Advanced Squamous NSCLC
Mark A. Socinski, Coleman K. Obasaju, David R. Gandara, Fred R. Hirsch, Philip Bonomi, Paul A. Bunn, Edward S. Kim, Corey Jay Langer, Ronald B. Natale, Silvia Novello et al. · 2016 · Journal of Thoracic Oncology
Immunomodulation by ionizing radiation—impact for design of radio‐immunotherapies and for treatment of inflammatory diseases
Benjamin Frey, Michael Rückert, Lisa Deloch, Paul F. Rühle, Anja Derer, Rainer Fietkau, Udo S. Gaipl · 2017 · Immunological Reviews
The World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the Globe
Florentia Dimitriou, Regina Krattinger, Egle Ramelyte, Marjam Jeanette Barysch, Sara Micaletto, Reinhard Dummer, Simone M. Goldinger · 2018 · Current Oncology Reports
Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades
Hao Chen, Wei Chong, Qian Wu, Yueliang Yao, Min Mao, Xin Wang · 2019 · Frontiers in Immunology
The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine
Andrea Garofalo, Lynette Marie Sholl, Brendan Michael Reardon, Amaro N Taylor-Weiner, Ali Amin‐Mansour, Diana Miao, David Liu, Nelly M. Oliver, Laura E. MacConaill, Matthew D. Ducar et al. · 2016 · Genome Medicine
Genomic Approaches to Understanding Response and Resistance to Immunotherapy
David A. Braun, Kelly P. Burke, Eliezer M. Van Allen · 2016 · Clinical Cancer Research
Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options
Derya Kabacaoğlu, Katrin J. Ciecielski, Dietrich Alexander Ruess, Hana Algül · 2018 · Frontiers in Immunology
Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy
Shixiang Wang, Li An Cowley, Xuesong Liu · 2019 · Molecules
Transcription factor c-Maf is a checkpoint that programs macrophages in lung cancer
Min Liu, Zan Tong, Chuanlin Ding, Fengling Luo, Shouzhen Wu, Caijun Wu, Sabrin Albeituni, Liqing He, Xiaoling Hu, David A. Tieri et al. · 2020 · Journal of Clinical Investigation
α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas
Dodagatta-Marri, E., Meyer, D. S., Reeves, M. Q., Paniagua, R., To, M. D., Binnewies, M., Broz, M. L., Mori, H., Wu, D., Adoumie, M. et al. · 2019 · Journal for ImmunoTherapy of Cancer
Next generation sequencing‐based gene panel tests for the management of solid tumors
Masayuki Nagahashi, Yoshifumi Shimada, Hiroshi Ichikawa, Hitoshi Kameyama, Kazuaki Takabe, Shujiro Okuda, Toshifumi Wakai · 2018 · Cancer Science
T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors
Takayoshi Yamauchi, Toshifumi Hoki, Takaaki Oba, Vaibhav Jain, Hongbin Chen, Kristopher M. Attwood, Sebastiano Battaglia, Saby George, Gurkamal S. Chatta, Igor J. Puzanov et al. · 2021 · Nature Communications
Technological advances in cancer immunity: from immunogenomics to single‐cell analysis and artificial intelligence
Xu, Ying, Su, Guan-Hua, Ma, Ding, Xiao, Yi, Shao, Zhi-Ming, Jiang, Yi-Zhou · 2021 · Signal Transduction and Targeted Therapy
High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer
Yusuke Okuma, Yukio Hosomi, Yoshiro Nakahara, Kageaki Watanabe, Yukiko Sagawa, Sadamu Homma · 2016 · Lung Cancer
Tobacco Smoking-Associated Alterations in the Immune Microenvironment of Squamous Cell Carcinomas
Alexis Desrichard, Fengshen Kuo, Diego Chowell, Ken-Wing Lee, Nadeem Riaz, Richard J. Wong, Timothy An-thy Chan, Luc G.T. Morris · 2018 · JNCI Journal of the National Cancer Institute
Inhibitors of the PD-1 Pathway in Tumor Therapy
Martin W. LaFleur, Yuki Muroyama, Charles G. Drake, Arlene H. Sharpe · 2018 · The Journal of Immunology
Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
Amy L. Shergold, Rhona Millar, Robert J. B. Nibbs · 2019 · Pharmacological Research
Development of immune checkpoint therapy for cancer
Jill M. Fritz, Michael J. Lenardo · 2019 · The Journal of Experimental Medicine
Chemical Strategies to Boost Cancer Vaccines
Wenhao Li, Yanmei Li · 2020 · Chemical Reviews
Prediction of neo-epitope immunogenicity reveals TCR recognition determinants and provides insight into immunoediting
Julien Schmidt, Angela R. Smith, Morgane Magnin, Julien Racle, Jason R. Devlin, Sara Bobisse, Julien Cesbron, Victor Bonnet, Santiago J. Carmona, Florian Huber et al. · 2021 · Cell Reports Medicine
The role of neoantigens in response to immune checkpoint blockade
Nadeem Riaz, Luc G.T. Morris, Jonathan J. Havel, Vladimir Makarov, Alexis Desrichard, Timothy An-thy Chan · 2016 · International Immunology
Identification of an immune signature predicting prognosis risk of patients in lung adenocarcinoma
Qian Song, Jun Shang, Zuyi Yang, Lanlin Zhang, Chufan Zhang, Jianing Chen, Xianghua Wu · 2019 · Journal of Translational Medicine
A comprehensive review and performance evaluation of bioinformatics tools for HLA class I peptide-binding prediction
Shutao Mei, Fuyi Li, André Leier, Tatiana T. Marquez‐Lago, Kailin Giam, Nathan P. Croft, Tatsuya Akutsu, A. Ian Smith, Jian Li, Jamie Rossjohn et al. · 2019 · Briefings in Bioinformatics
Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities
KM Morrissey, Theresa M. Yuraszeck, Chi‐Chung Li, Y Zhang, Sreeneeranj Kasichayanula · 2016 · Clinical and Translational Science
Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells
Elliott Joseph Brea, Claire Y. Oh, Eusebio Manchado, Sadna Budhu, Ron S. Gejman, George Mo, Patrizia Mondello, James E. Han, Casey A. Jarvis, David Ulmert et al. · 2016 · Cancer Immunology Research
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable
Thanyanan Reungwetwattana, Ying Liang, Viola Weijia Zhu, Sai‐Hong Ignatius Ou · 2016 · Lung Cancer
Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling
Alexa Betzig Schrock, Shuyu Dan Li, Garrett Michael Frampton, James H. Suh, Eduardo Braun, Ranee Mehra, Steven C. Buck, José A. Bufill, Nir Peled, Nagla Abdel Karim et al. · 2017 · Journal of Thoracic Oncology
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Laurence P. Diggs, Eddy C. Hsueh · 2017 · Biomarker Research
PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer
Katerina Ancevski Hunter, Mark A. Socinski, Liza Cosca Villaruz · 2017 · Molecular Diagnosis & Therapy
KEYNOTE-590: Phase III Study of First-Line Chemotherapy with or Without Pembrolizumab for Advanced Esophageal Cancer
Ken Kato, Manish A. Shah, Peter C. Enzinger, Jaafar Bennouna, Lin Shen, Antoine Adenis, Jong‐Mu Sun, Byoung Chul Cho, Mustafa Özgüroğlu, Takashi Kojima et al. · 2019 · Future Oncology
Increased glycolysis correlates with elevated immune activity in tumor immune microenvironment
Zehang Jiang, Zhixian Liu, Mengyuan Li, Cai Chen, Xiaosheng Wang · 2019 · EBioMedicine
Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer
Sandra Assoun, Nathalie Théou–Anton, Marina Nguenang, Aurélie Cazes, Claire J. Danel, Baptiste Abbar, Johan Pluvy, Valérie Gounant, Antoine Khalil, Céline Namour et al. · 2019 · Lung Cancer
Genomic landscape of DNA repair genes in cancer
Young Kwang Chae, Jonathan Forrest Anker, Benedito A. Carneiro, Sunandana Chandra, Jason Benjamin Kaplan, Aparna Kalyan, Cesar Augusto Santa-Maria, Leonidas C. Platanias, Francis Joseph Giles · 2016 · Oncotarget
Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer
Lydia Meder, Philipp Schuldt, Martin Thelen, Anna Schmitt, Felix Dietlein, Sebastian Klein, Sven Borchmann, Kerstin Wennhold, Ignacija Vlašić, Sebastian Oberbeck et al. · 2018 · Cancer Research
Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract
Michael Lawrence Dougan · 2017 · Frontiers in Immunology
Prognostic Impact of Tumor Mutation Burden in Patients With Completely Resected Non–Small Cell Lung Cancer: Brief Report
Yuki Owada, Satoshi Muto, Hironori Takagi, Takuya Inoue, Yuzuru Watanabe, Mitsuro Fukuhara, Takumi Yamaura, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa et al. · 2018 · Journal of Thoracic Oncology
Predicting Antigen Presentation—What Could We Learn From a Million Peptides?
David Gfeller, Michal Bassani‐Sternberg · 2018 · Frontiers in Immunology
Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade
Petar Jelinic, Jacob M. Ricca, Elke Van Oudenhove, Narciso Olvera, Taha Merghoub, Douglas A. Levine, Dmitriy Zamarin · 2017 · JNCI Journal of the National Cancer Institute
Genomic profiling in renal cell carcinoma
Nazlı Dizman, Errol James Philip, Sumanta Kumar Pal · 2020 · Nature Reviews Nephrology
COMPASS Ascending: Emerging clues regarding the roles of MLL3/KMT2C and MLL2/KMT2D proteins in cancer
Richard J. Fagan, Andrew K. Dingwall · 2019 · Cancer Letters
Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations
Jordi Remón, Francesco Passiglia, Myung‐Ju Ahn, Fabrice Barlési, Patrick M. Forde, Edward B. Garon, Scott N. Gettinger, Sarah B. Goldberg, Roy S. Herbst, Leora Horn et al. · 2020 · Journal of Thoracic Oncology
Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment
Bo Wu, Xiang Shi, Meixi Jiang, Hongxu Liu · 2023 · Molecular Cancer
Translating cancer genomes and transcriptomes for precision oncology
Sameek Roychowdhury, Arul M. Chinnaiyan · 2015 · CA A Cancer Journal for Clinicians
Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer
Heather L. Kinkead, Alexander C. Hopkins, Eric R. Lutz, Annie A. Wu, Mark M. Yarchoan, Kayla A. Cruz, Skylar Woolman, Teena Vithayathil, Laura Hix Glickman, Chudi O. Ndubaku et al. · 2018 · JCI Insight
Tumor mutation burden: from comprehensive mutational screening to the clinic
Francesca Galuppini, Carlo Alberto Dal Pozzo, Jutta Deckert, Fotios Loupakis, Matteo Fassan, Raffaele Baffa · 2019 · Cancer Cell International
The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy
Todd Cory Knepper, Meagan Montesion, Jeffery Scott Russell, Ethan S. Sokol, Garrett Michael Frampton, Vincent A. Miller, Lee A. Albacker, Howard L. McLeod, Zeynep Eroglu, Nikhil I. Khushalani et al. · 2019 · Clinical Cancer Research
Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer
Zhao, Sha, Gao, Guanghui, Li, Wei, Li, Xuefei, Zhao, Chao, Jiang, Tao, Jia, Yijun, He, Yayi, Li, Aiwu, Su, Chunxia et al. · 2019 · Lung Cancer
Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches
Aaron M. Udager, Ting‐yu Liu, Stephanie L. Skala, Martin J. Magers, Andrew S. McDaniel, Daniel Eidelberg Spratt, Felix Yi-Chung Feng, Javed Siddiqui, Xuhong Cao, Kristina L. Fields et al. · 2016 · Annals of Oncology
PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung
Sehui Kim, Jaemoon Koh, Moon‐Young Kim, Dohee Kwon, Heounjeong Go, Young A Kim, Yoon Kyung Jeon, Doo Hyun Chung · 2016 · Human Pathology
Advances in Cancer Immunotherapy in Solid Tumors
Smitha Patiyil Menon, Sarah J. Shin, Grace Kho Dy · 2016 · Cancers
Clinical and Pathological Characteristics of KEAP1 - and NFE2L2 -Mutated Non–Small Cell Lung Carcinoma (NSCLC)
Rieke Frank, Matthias Scheffler, Sabine Merkelbach‐Bruse, Michaela A. Ihle, Anna Kron, Michael Rauer, Frank Ueckeroth, Katharina König, Sebastian Yves Friedrich Michels, Rieke Nila Fischer et al. · 2018 · Clinical Cancer Research
PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside
Anita Ahmed Turk, Kari Braun Wisinski · 2018 · Cancer
Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF)
Hendrik‐Tobias Arkenau, Juan Martín-Liberal, Emiliano Calvo, Nicolas Penel, Matthew Krebs, Roy S. Herbst, Richard A. Walgren, Ryan C. Widau, Gu Mi, Jin Jin et al. · 2018 · The Oncologist
Targeting Hypoxia-Induced Carbonic Anhydrase IX Enhances Immune-Checkpoint Blockade Locally and Systemically
Shawn C. Chafe, Paul C. McDonald, Saeed Saberi, Oksana Nemirovsky, Geetha Venkateswaran, Samantha Burugu, Dongxia Gao, Alberto Delaidelli, Alastair Hugh Kyle, Jennifer H.E. Baker et al. · 2019 · Cancer Immunology Research
Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity
Valsamo Anagnostou, Mark M. Yarchoan, Aaron Richard Hansen, Hao Wang, Franco Verde, Elad Sharon, Deborah E. Collyar, Laura Q.M. Chow, Patrick M. Forde · 2017 · Clinical Cancer Research
Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers
Muhammad Umair Mushtaq, Athanasios Papadas, Adam C. Pagenkopf, Evan Flietner, Zachary T. Morrow, Sibgha Gull Chaudhary, Fotis A. Asimakopoulos · 2018 · Journal for ImmunoTherapy of Cancer
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis
Francesco Passiglia, Giuseppe Bronte, Viviana Bazan, Clara Natoli, Sérgio Rizzo, Antonio Galvano, Angela Listì, Giuseppe Cicero, Christian Diego Rolfo, Daniele Santini et al. · 2016 · Oncotarget
Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine
Conway, Jake R., Kofman, Eric, Mo, Shirley S., Elmarakeby, Haitham, Van Allen, Eliezer · 2018 · Genome Medicine
TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials
Khalil Choucair, Susan M. Morand, Laura Stanbery, Gerald M. Edelman, Lance D. Dworkin, John J. Nemunaitis · 2020 · Cancer Gene Therapy
Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance
Felicity Newell, Inês Pires da Silva, Peter A. Johansson, Alexander Maxwell Menzies, James S. Wilmott, Venkateswar Addala, Matteo Salvatore Carlino, Helen Rizos, Kátia Nones, Jarem J. Edwards et al. · 2021 · Cancer Cell
Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors
Răzvan Cristescu, Deepti Aurora-Garg, Andrew V Albright, Lei Xu, Xiao Qiao Liu, Andrey P. Loboda, Lixin Lang, Fan Jin, Eric H. Rubin, Alexandra Snyder et al. · 2022 · Journal for ImmunoTherapy of Cancer
Dysregulation and therapeutic targeting of RNA splicing in cancer
Robert F. Stanley, Omar Ibrahim Abdel-Wahab · 2022 · Nature Cancer
Landscape of Tumor Antigens in T Cell Immunotherapy
Sadia Ilyas, James Chih‐Hsin Yang · 2015 · The Journal of Immunology
Biomarkers associated with checkpoint inhibitors
Guillaume Manson, J. Norwood, Aurélien Marabelle, Holbrook E K Kohrt, Roch Houot · 2016 · Annals of Oncology
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Benjamin Herzberg, Meghan J. Campo, Justin F. Gainor · 2016 · The Oncologist
Genetic Features of Aflatoxin-Associated Hepatocellular Carcinoma
Weilong Zhang, Huan He, Mengya Zang, Qifeng Wu, Hong Zhao, Ling-ling Lu, Peiqing Ma, Hongwei Zheng, Neng-Jin Wang, Ying Zhang et al. · 2017 · Gastroenterology
Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?
Joseph A. Pinto, Carlos Santiago Vallejos, Luis Estuardo Raez, Luis A. Mas, Rossana Ruiz, Junior Smith Torres-Román, Zaida Morante, Jhajaira M. Araujo, Henry Gómez, Alfredo Aguilar et al. · 2018 · ESMO Open
Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement
Douglas Buckner Johnson, Mellissa J. Nixon, Yu Wang, Daniel Y. Wang, Emily H. Castellanos, Monica Valeria Estrada, Paula I. González Ericsson, Candace H. Cote, Roberto Salgado, Violeta M. Sanchez et al. · 2018 · JCI Insight
Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma
Celina Ang, Samuel Jacob Klempner, Siraj Mahamed Ali, Russell William Madison, Jeffrey S. Ross, Eric Allan Severson, David A. Fabrizio, Aaron Michael Goodman, Razelle Kurzrock, James H. Suh et al. · 2019 · Oncotarget
Harnessing non-destructive 3D pathology
Jonathan T.C. Liu, Adam K. Glaser, Kaustav Bera, Lawrence D. True, Nicholas P. Reder, Kevin W. Eliceiri, Anant Madabhushi · 2021 · Nature Biomedical Engineering
Molecular determinants of response to PD-L1 blockade across tumor types
Romain Banchereau, Ning Leng, Oliver A. Zill, Ethan S. Sokol, Gengbo Liu, Dean Pavlick, Sophia Lisette Maund, Li-Fen Liu, Edward Ernest Kadel, Nicole E. Baldwin et al. · 2021 · Nature Communications
Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision
Leisha A. Emens, Pedro J. Romero, Ana Carrizosa Anderson, Tullia Carmela Bruno, Christian M. Capitini, Deborah E. Collyar, James L. Gulley, Patrick Hwu, Avery D. Posey, Ann Willman Silk et al. · 2024 · Journal for ImmunoTherapy of Cancer
Tumour mutational burden: clinical utility, challenges and emerging improvements
Jan Budczies, Daniel N. Kazdal, Michael Menzel, Susanne Beck, Klaus Kluck, Christian Altbürger, Constantin Schwab, Michael Allgäuer, Aysel Ahadova, Matthias Kloor et al. · 2024 · Nature Reviews Clinical Oncology
Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non–small cell lung cancer (NSCLC)
Ricciuti, Biagio, Jones, Greg, Severgnini, Mariano, Alessi, Joao V, Recondo, Gonzalo, Lawrence, Marissa, Forshew, Tim, Lydon, Christine, Nishino, Mizuki, Cheng, Michael et al. · 2021 · Journal for ImmunoTherapy of Cancer
Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease
Crispin T. Hiley, John P. C. Le Quesne, George Santis, Rowena Sharpe, David González de Castro, Gary Middleton, Charles Swanton · 2016 · The Lancet